Article
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
BMC cancer - 3 Jan 2018
Huemer Florian, Thaler Josef, Piringer Gudrun, Hackl Hubert, Pleyer Lisa, Hufnagl Clemens, Weiss Lukas, Greil Richard
Abstract excerpt
BACKGROUND: In metastatic colorectal cancer (mCRC), the localization of the primary tumour has been shown to be of prognostic as well as predictive relevance. METHODS: With the aim to investigate clinical and molecular disease characteristics with respect to sidedness in a real-world cohort, we analyzed 161 mCRC patients included in the KRAS Registry of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.